Phosphorylated AKT protein is overexpressed in human peripheral T-cell lymphomas and predicts decreased patient survival

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 2, 2012, Pages 106-112

  Cai, Qingqing ^a,b   Deng, Haixia ^b   Xie, Dan ^b   Lin, Tianxin ^a   Lin, Tongyu ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Immunohistochemistry; Peripheral T cell lymphoma; Phosphorylated AKT; Prognosis

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; METHOTREXATE; PHOSPHOPROTEIN; PREDNISONE; PROTEIN KINASE B; VINCRISTINE; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PATHOLOGY; PERIPHERAL T CELL LYMPHOMA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84858986248     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.12.002     Document Type: Article

References (35)

1. Rodríguez J, Gutiérrez A, Martínez-Delgado B, et al. Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. Crit Rev Oncol Hematol 2009; 71:181-98.
2. Gallamini A, Stelitano C, Calvi R, et al. Pripheral T-cell lymphoma unspecified (PTCL-U): a new prognosis model from a retrospective multicentric clinical study. Blood 2004; 103:2474-9. (Pubitemid 38392996)
3. Huang JJ, Jiang WQ, Lin TY, et al. Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol 2011; 22:149-55.
4. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111:5496-504.
5. Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006; 24:2472-9. (Pubitemid 46630624)
6. Bellacosa A, Kumar CC, Di Cristofano A, et al. Activation of AKT kinase in cancer: implication for therapeutic targeting. Adv Cancer Res 2005; 94:29-86. (Pubitemid 41202364)
7. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501. (Pubitemid 37328931)
8. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002; 86:540-5. (Pubitemid 34185089)
9. Saetta AA, Levidou G, El-Habr EA, et al. Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial, growth factor, microvascular characteristics and clinical outcome. Virchows Arch 2011; 458:749-59.
10. Uddin S, Hussain AR, Siraj AK, et al. Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006; 108:4178-86. (Pubitemid 44913290)
11. Hasselblom S, Hansson U, Olsson M, et al. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Br J Haematol 2010; 149:560-8.
12. Murakami D, Tsujitani S, Osaki T, et al. Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy. Gastric Cancer 2007; 10:45-51. (Pubitemid 46356263)
13. Bedolla R, Prihoda TJ, Kreisberg JI, et al. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 2007; 13:3860-7. (Pubitemid 47037592)
14. Song CH, Park SY, Eom KY, et al. Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers. Breast Cancer Res 2010; 12:R20.
15. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:1244-53. (Pubitemid 29162950)
16. Alessi DR, Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 1998; 8:55-62. (Pubitemid 28122141)
17. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129:1261-74. (Pubitemid 46962095)
18. Romasshkova JA, Makarov SS. NFκB is a target of AKT in anti-apoptotic PDGF signaling. Nature 1999; 401:86-90.
19. Hager M, Haufe H, Lusuardi L, et al. PTEN, pAKT, and pmTOR expression and subcellular distribution in primary renal cell carcinomas and their metastases. Cancer Invest 2011; 29:427-38.
20. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005; 24:7455-64. (Pubitemid 41637985)
21. Teng DH, Hu R, Lin H, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997; 57:5221-5. (Pubitemid 27516352)
22. Dahia PL, Aguiar RC, Alberta J, et al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanism in haematological malignancies. Hum Mol Genet 1999; 8:185-93. (Pubitemid 29054260)
23. Kreisberg JI, Malik SN, Prihoda TJ, et al. Phosphorylation of AKT(Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004; 64:5232-6. (Pubitemid 39006542)
24. Brognard J, Clark AS, Ni Y, et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61:3986-97. (Pubitemid 32720961)
25. Brognard J, Dennis PA. Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Differ 2002; 9:893-904. (Pubitemid 35023605)
26. Clark AS, West K, Streicher S, et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002; 1:707-17.
27. Clark AS, West KA, Blumberg PM, et al. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res 2003; 63:780-6. (Pubitemid 36231976)
28. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Update 2002; 5:234-48. (Pubitemid 36132805)
29. Balendran A, Casamayor A, Deak M, et al. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr Biol 1999; 9:393-404. (Pubitemid 29205782)
30. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282:1318-21. (Pubitemid 28524494)
31. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96:857-68. (Pubitemid 29165088)
32. Barancík M, Bohácová V, Sedlák J, et al. LY294002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 2006; 29:426-34. (Pubitemid 44709864)
33. Cordo Russo RI, García MG, Alaniz L, et al. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway. Int J Cancer 2008; 122:1012-8. (Pubitemid 351213998)
34. García MG, Alaniz LD, Cordo Russo RI, et al. PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines. Leuk Res 2009; 33:288-96.
35. Shi Y, Chen L, Li J, et al. Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy. Tumour Biol 2011; 32:381-90.